Osram Licht (OTCMKTS:OSAGF) and Hikma Pharmaceuticals (OTCMKTS:HKMPF) are both mid-cap computer and technology companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Earnings and Valuation

This table compares Osram Licht and Hikma Pharmaceuticals’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Osram Licht $4.56 billion 0.94 $244.18 million $3.73 10.99
Hikma Pharmaceuticals $1.94 billion 2.66 $252.91 million $1.05 20.38

Hikma Pharmaceuticals has lower revenue, but higher earnings than Osram Licht. Osram Licht is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Osram Licht and Hikma Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Osram Licht 4.40% 10.07% 5.88%
Hikma Pharmaceuticals N/A N/A N/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for Osram Licht and Hikma Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Osram Licht 0 3 0 0 2.00
Hikma Pharmaceuticals 0 0 1 0 3.00

Risk & Volatility

Osram Licht has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, Hikma Pharmaceuticals has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.

Summary

Osram Licht beats Hikma Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About Osram Licht

OSRAM Licht AG provides various lighting products and solutions worldwide. The company operates through Specialty Lighting, Opto Semiconductors, and Lighting Solutions & Systems segments. The Specialty Lighting segment develops and produces lamps and lighting systems for the automotive sector, studio, stage and TV, and projection system applications, as well as special lamps for industrial and medical applications; produces lamps for disinfecting liquids, surfaces, and gases with UV light. The Opto Semiconductors segment manufactures optoelectronic semiconductors, such as light-emitting diode (LED), optical sensors, infrared LED, and high-power laser diodes for visible and infrared light. This segment's products are used in automotive, communication products, and consumer goods industries. The Lighting Solutions & Systems segment develops, produces, and markets LED light engines, electronic ballasts for LED modules and traditional lamps, and light management systems. This segment also provides luminaires for professional applications, such as street lighting or architectural lighting, as well as for private applications, including table lamps and flashlights; and lighting solutions and associated light management systems that are used in internal and external architectural lighting, and in event lighting, as well as offers installation and maintenance services for its product portfolio. The company offers its products primarily under the OSRAM, SYLVANIA, SYLVANIA Lighting Solutions, Siteco, Traxon, Clay Paky, and LUX365 brand names. The company was formerly known as Kyros A AG and changed its name to OSRAM Licht AG in November 2012. OSRAM Licht AG was founded in 1906 and is headquartered in Munich, Germany.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products. The Generics segment develops and sells approximately 100 oral and other non-injectable generic products for oncology and pain management, as well as respiratory, nasal spray, suspension, liquid solution, and high-containment areas. The Branded segment develops, manufactures, and markets branded generics and in-licensed products, such as anti-infective products, as well as chronic therapeutic categories comprising cardiovascular, diabetes, CNS, and oncology products. The company also manufactures plastic specialized medicinal sterile containers and APIs; and conducts bio-equivalency studies. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Receive News & Ratings for Osram Licht Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osram Licht and related companies with MarketBeat.com's FREE daily email newsletter.